Yong Xiang Wang
Directeur/Membre du Conseil chez SIRNAOMICS LTD.
Profil
Yong Xiang Wang is currently the Executive Director & Chief Production Officer at Sirnaomics Ltd.
Prior to this, he held positions as the Director-Vaccine Production at NewLink Genetics Corp.
from 2014 to 2016, Deputy Director-Engineering at Aeras Global TB Vaccine Foundation from 2007 to 2011, Technology Director at Charter Medical Ltd.
in 2005-2006, Technology Consultant-Parexel International at Ben Venue Laboratories, Inc. from 2011 to 2012, and Vice President-Technical Operations at WuXi AppTec Co., Ltd.
from 2012 to 2014.
He also served as the Deputy General Manager at Shanghai Furen Medicine R&D Co., Ltd.
from 2016 to 2018.
Dr. Wang completed his undergraduate studies at the University of Science & Technology of China in 1976, followed by a graduate degree from Tokyo Institute of Technology in 1983, and a doctorate from Aalto University School of Science & Technology in 1995.
Postes actifs de Yong Xiang Wang
| Sociétés | Poste | Début |
|---|---|---|
| SIRNAOMICS LTD. | Directeur/Membre du Conseil | 10/05/2024 |
Anciens postes connus de Yong Xiang Wang
| Sociétés | Poste | Fin |
|---|---|---|
| Shanghai Furen Medicine R&D Co., Ltd. | Corporate Officer/Principal | 01/06/2018 |
| LUMOS PHARMA, INC. | Corporate Officer/Principal | 01/06/2016 |
| WUXI APPTEC CO., LTD. | Corporate Officer/Principal | 01/02/2014 |
Ben Venue Laboratories, Inc.
 Ben Venue Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Ben Venue Laboratories, Inc. develops and manufactures sterile liquid products. Its products include Lyophilized Dosages, Small Molecule Pharmaceuticals, Cytotoxics, and Potent Compounds. The company was founded by R. Templeton Smith in 1938 and is headquartered in Bedford, OH. | Corporate Officer/Principal | 01/10/2012 |
Aeras Global TB Vaccine Foundation
 Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Corporate Officer/Principal | 01/10/2011 |
Formation de Yong Xiang Wang
| University of Science & Technology of China | Undergraduate Degree |
| Tokyo Institute of Technology | Graduate Degree |
| Aalto University School of Science & Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SIRNAOMICS LTD. | Health Technology |
| WUXI APPTEC CO., LTD. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Charter Medical Ltd.
 Charter Medical Ltd. BiotechnologyHealth Technology Charter Medical has an established history of providing specialty products to the blood transfusion and cell therapies and single-use bioprocessing containers to the biotechnology and pharmaceutical markets. Charter Medical was formed in 1998, a privately held medical device manufacturer of disposable blood transfusion and intravenous products located in Lakewood, NJ. Charter Medical continued production of the existing CharterMed medical devices and expanded the product line to include bioprocessing bags. Manufacturing began at the Winston-Salem headquarters in 1998 in one ISO Class 8 cleanroom. In 2001, Charter Medical commissioned a second cleanroom at the 71,000 square foot site to expand the medical device and bioprocessing bag manufacturing capabilities. Through a second expansion in 2009, Charter Medical now houses 15,000 square feet of clean room space to support the ever growing demand for disposable products. | Health Technology |
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Commercial Services |
Ben Venue Laboratories, Inc.
Ben Venue Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Ben Venue Laboratories, Inc. develops and manufactures sterile liquid products. Its products include Lyophilized Dosages, Small Molecule Pharmaceuticals, Cytotoxics, and Potent Compounds. The company was founded by R. Templeton Smith in 1938 and is headquartered in Bedford, OH. | Health Technology |
| Shanghai Furen Medicine R&D Co., Ltd. | |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |